GSK_Annual_Report_2021

Financial Statements GlaxoSmithKline Pharmaceuticals Limited 96 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 A. CASH FLOWS FROM OPERATING ACTIVITIES Profit before exceptional items and tax 722,33.31 646,99.24 Adjustments for : Loss/ (Gain) on disposal of property, plant and equipment (net) 5.88 (2,33.36) Interest income (110,18.78) (75,22.20) Finance costs 3,53.14 6,33.55 Depreciation and amortisation expense 79,28.36 82,67.77 Allowance for doubtful debts and advances 2,06.05 2,74.08 Operating Profit before working capital changes 697,07.96 661,19.08 Change in operating assets and liabilities (Increase) in inventories (23,43.34) (67,71.67) (Increase) in trade receivables (99,93.42) (4.97) (Increase) / Decrease in other assets (2,51.33) 148,00.45 Increase / (Decrease) in trade payables 92,14.19 (48,24.95) Increase in provisions 27,08.09 12,77.16 Increase/ (Decrease) in other liabilities 69,68.99 (1,16.77) Cash generated from operations 760,11.14 704,78.33 Income taxes paid (net of refunds) (146,91.85) (185,70.86) Cash inflow from operating activities before exceptional items 613,19.29 519,07.47 Exceptional items: Sale of brands - 50.69 Payment of Associated cost to impairment (7,03.09) (7,13.89) Payment of redundancy cost (11,30.59) (27,63.21) Income taxes on exceptional items 0.93 6,16.28 Net cash inflow from operating activities A 594,86.54 490,97.34 B. CASH FLOWS FROM INVESTING ACTIVITIES Payments to acquire property, plant and equipment and other intangible assets (44,22.66) (155,89.81) Proceeds from sale of property, plant and equipment 67.20 3,49.96 Margin money deposits 14.33 29.81 Investment in bank deposits (having original maturity more than 3 months but less than 12 months) (3305,23.00) (1106,00.00) Redemption / maturity of bank deposits (having original maturity more than 3 months but less than 12 months) 3520,23.00 1193,00.00 Interest received 54,55.98 64,01.16 Changes in earmarked balances 57.98 1,80.70 Cash inflow from investing activities before exceptional items 226,72.83 71.82 Exceptional items: Proceeds /(expenses incurred) from for sale of property 1,84.09 (2,48.24) Advance received towards disposal of Vemgal assets 180,00.00 - Income taxes on Exceptional items (42.12) (61,33.86) Net cash inflow/ (outflow) from investing activities B 408,14.80 (63,10.28) Standalone Cash Flow Statement for the year ended March 31, 2021